The U.S. Food and Drug Administration (FDA) cleared the FreeStyle Libre 3 real-time continuous glucose monitoring (CGM) system (Abbott Diabetes Care) for use in May 2022. This system is an update of the FreeStyle Libre 2 and offers CGM with alarm capability for current or impending high and low glucose levels. The Libre 3 system measures glucose levels every minute and automatically sends the results to a smartphone without requiring users to scan the sensor to see their glucose concentrations. In contrast, the Libre 2 is an intermittently scanned, or “flash” CGM system that requires users to scan the sensor with a smartphone or reader device (1,2).

The FreeStyle Libre 3 is a single-use, disposable sensor that is applied to the back of the upper arm and can be worn for 14 days. This device is much more convenient than the previous iteration of the system...

You do not currently have access to this content.